19 March 2019 - The Biosimilars Forum and Medicines for Europe today released a joint white paper that discusses how Europe has successfully sustained its multisource biosimilars market for the past 10 years and calls on the United States to make structural changes in order to achieve similar success.

According to the white paper, despite the fact that US-led regulatory science and research made the European biosimilars market possible, the United States has yet to learn from Europe’s success in striking a balance between long-term sustainability and short-term savings. Currently, 90% of biosimilar sales take place in Europe, despite the fact that 60% of all biologic medicine sales occur in the United States.

The report explains that, as biosimilars have become available in Europe, patient access has increased while costs have dropped. In the United Kingdom, for example, after the arrival of biosimilars for infliximab, etanercept, and rituximab, prices for these therapies fell by an average of 40%, while overall volume rose by approximately 16%.

Read Center for Biosimilars press release